Bioaffinity Technologies, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. (Nasdaq: BIAF) on July 26, 2023. The report discloses a specific corporate governance event regarding executive compensation effective August 1, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on an amendment to an executive employment agreement.
Material Changes
The Company entered into an amendment to the employment agreement with Maria Zannes, Chief Executive Officer. The material change is an increase in her annual base salary to $260,000, effective August 1, 2023. All other terms of the original agreement dated February 1, 2015, remain in full force and effect.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies beyond the standard incorporation of the amendment text by reference.
Investor Verification Checklist
- Verify the full text of the employment amendment filed as Exhibit 10.1 to confirm all terms beyond the base salary adjustment.
- Review the Company's most recent 10-K or 10-Q filings for current financial performance and liquidity status, as this 8-K does not contain financial data.
- Confirm the effective date of the salary increase is August 1, 2023.